Etiological structure of infectious complications and microbial colonization in patients of COVID-19 hospital of a multidisciplinary federal medical institution

Abstract

BACKGROUND: Despite the proven importance of secondary bacterial infections influencing the severity of viral respiratory diseases, their etiology is still not well understood. There is a gap in knowledge about the nature, frequency, and antimicrobial resistance profiles of bacterial pathogens in the current COVID-19 pandemic.

AIM: To describe the species spectrum of microorganisms in patients of the COVID-19 Hospital on the basis of a multidisciplinary federal medical institution.

MATERIALS AND METHODS: Clinical samples (blood, lower respiratory tract discharge, urine, other biological materials) from patients with COVID-19 who were treated at the COVID-19 Hospital at a multidisciplinary federal medical institution were obtained and processed.

RESULTS: The bacteriological laboratory received 1821 samples of biomaterial from 452 patients, microorganisms were isolated from 620 (38.0%) samples. Most of the biomaterial was represented by blood — 35.9% and discharge from the lower respiratory tract — 31.7%. The structure of microorganisms was dominated by Candida albicans — 19.7%, Staphylococcus aureus — 10.2%, Klebsiella pneumoniae — 10.1%, Enterococcus faecalis — 7.9%. At the beginning of the period of operation of the Hospital, the most frequently identified microorganisms were S. aureus and Haemophilus influenzae — 19.7% and 7.9%, respectively, while in the final period there was a change in the spectrum of microorganisms to nosocomial ESKAPE -pathogens with multiple drug resistance, the structure was dominated by Acinetobacter baumannii — 24.3%. Antibiotic consumption in the hospital increased from 18.3 DDD/100 patient days in 2019 to 28.8 DDD/100 patient days in 2020.

CONCLUSION: Significant colonization of various loci of patients with COVID-19 by fungi of the genus Candida was revealed. There has been a change in the microbial spectrum of infectious agents from community-acquired (H. influenzae and S. pneumoniae) to nosocomial ESKAPE pathogens with multiple drug resistance. The consumption of antibiotics has increased significantly.

Keywords

COVID-19 / antimicrobials / antibiotic resistance / bacterial complications / colonization / antibiotic consumption

References

[1] Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) — recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006–2011. doi: 10.26355/eurrev_202002_20378

[2] Kannan S., Shaik Syed Ali P., Sheeza A., Hemalatha K. COVID-19 (Novel Coronavirus 2019) — recent trends // Eur Rev Med Pharmacol Sci. 2020. Vol. 24, N 4. P. 2006–2011. doi: 10.26355/eurrev_202002_20378

[3] Sifuentes-Rodríguez E, Palacios-Reyes D. COVID-19: The outbreak caused by a new coronavirus. Bol Med Hosp Infant Mex. 2020;77(2):47–53. doi: 10.24875/BMHIM.20000039

[4] Sifuentes-Rodríguez E., Palacios-Reyes D. COVID-19: The outbreak caused by a new coronavirus // Bol Med Hosp Infant Mex. 2020. Vol. 77, N 2. P. 47–53. doi: 10.24875/BMHIM.20000039

[5] Sharma B, Sreenivasan P, Biswal M, et al. Bacterial coinfections and secondary infections in COVID-19 patients from a tertiary care hospital of northern India: Time to adhere to culture-based practices. Qatar Med J. 2021;(3):62. doi: 10.5339/qmj.2021.62

[6] Sharma B., Sreenivasan P., Biswal M., et al. Bacterial coinfections and secondary infections in COVID-19 patients from a tertiary care hospital of northern India: Time to adhere to culture-based practices // Qatar Med J. 2021. N 3. P. 62. doi: 10.5339/qmj.2021.62

[7] Kuzmenkov AYu, Vinogradova AG, Trushin IV, et al. AMRcloud: a new paradigm in monitoring of antibiotic resistance. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(2):119–124. (In Russ). doi: 10.36488/cmac.2019.2.119-124

[8] Кузьменков А.Ю., Виноградова А.Г., Трушин И.В., и др. AMRcloud: новая парадигма мониторинга антибиотикорезистентности // Клиническая микробиология и антимикробная химиотерапия. 2019. Т. 21, № 2. С. 119–124. doi: 10.36488/cmac.2019.2.119-124

[9] Archive of EUCAST tables and documents [Internet]. [cited 2022 Sept 2]. Available from: https://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/.

[10] Archive of EUCAST tables and documents [интернет]. [дата обращения: 02.09.2022]. Доступ по ссылке: https://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/.

[11] Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568–576. doi: 10.1002/jmv.25748

[12] Wang Y., Wang Y., Chen Y., Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures // J Med Virol. 2020. Vol. 92, N 6. P. 568–576. doi: 10.1002/jmv.25748

[13] Garcia-Vidal C, Sanjuan G, Moreno-García E, et al.; COVID-19 Researchers Group. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83–88. doi: 10.1016/j.cmi.2020.07.041

[14] Garcia-Vidal C., Sanjuan G., Moreno-García E., et al.; COVID-19 Researchers Group. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study // Clin Microbiol Infect. 2021. Vol. 27, N 1. P. 83–88. doi: 10.1016/j.cmi.2020.07.041

[15] Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12. doi: 10.1086/595011

[16] Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America // Clin Infect Dis. 2009. Vol. 48, N 1. P. 1–12. doi: 10.1086/595011

[17] Yu D, Ininbergs K, Hedman K, et al. Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19. PLoS One. 2020;15(11):e0242533. doi: 10.1371/journal.pone.0242533

[18] Yu D., Ininbergs K., Hedman K., et al. Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19 // PLoS One. 2020. Vol. 15, N 11. P. e0242533. doi: 10.1371/journal.pone.0242533

[19] Karpov OE, Gusarov VG, Zamyatin MN, et al. Management of antimicrobial resistance in a hospital: current state and future prospects. Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(4):277–286. (In Russ). doi: 10.36488/cmac.2020.4.277-286

[20] Карпов О.Э., Гусаров В.Г., Замятин М.Н., и др. Управление антибиотикорезистентностью в стационаре: современные реалии и перспективы // Клиническая микробиология и антимикробная химиотерапия. 2020. Т. 22, № 4. С. 277–286. doi: 10.36488/cmac.2020.4.277-286

[21] Palagin IS, Sukhorukova MV, Dekhnich AV, et al. DARMIS-2018 Study Group. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(2):134–146. (In Russ). doi: 10.36488/cmac.2019.2.134-146

[22] Палагин И.С., Сухорукова М.В., Дехнич А.В., и др.; Исследовательская группа «ДАРМИС-2018». Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018» // Клиническая микробиология и антимикробная химиотерапия. 2019. Т. 21, № 2. С. 134–146. doi: 10.36488/cmac.2019.2.134-146

[23] Martinez-Guerra BA, Gonzalez-Lara MF, de-Leon-Cividanes NA, et al. Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic. Antibiotics (Basel). 2021;10(2):182. doi: 10.3390/antibiotics10020182

[24] Martinez-Guerra B.A., Gonzalez-Lara M.F., de-Leon-Cividanes N.A., et al. Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic // Antibiotics (Basel). 2021. Vol. 10, N 2. P. 182. doi: 10.3390/antibiotics10020182

[25] Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520–531. doi: 10.1016/j.cmi.2020.12.018

[26] Langford B.J., So M., Raybardhan S., et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis // Clin Microbiol Infect. 2021. Vol. 27, N 4. P. 520–531. doi: 10.1016/j.cmi.2020.12.018

[27] Mirzaei R, Goodarzi P, Asadi M, et al. Bacterial co-infections with SARS-CoV-2. IUBMB Life. 2020;72(10):2097–2111. doi: 10.1002/iub.2356

[28] Mirzaei R., Goodarzi P., Asadi M., et al. Bacterial co-infections with SARS-CoV-2 // IUBMB Life. 2020. Vol. 72, N 10. P. 2097–2111. doi: 10.1002/iub.2356

RIGHTS & PERMISSIONS

Petrova L.V., Mironov A.Y., Gusarov V.G., Kamyshova D.A., Khakulova A.E., Zamyatin M.N., Suranova T.G.